Results 91 to 100 of about 2,581 (157)

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapies on Liver Transplant Outcomes. [PDF]

Gastro Hep Adv
Naimimohasses S, Ray A, Tan E, Wiggins A, Hasjim BJ, Chen S, Bhat M.   +6 more
europepmc   +1 more source

Red blood cell deformability as a mechanobiological marker of CFTR dysfunction in cystic fibrosis. [PDF]

iScience
Pero E, Tomaiuolo G, Villella VR, Esposito S, Vetrone MA, Panarelli A, Castaldo A, Sepe A, Andolfo I, Tosco A, Castaldo G, Raia V, Guido S.   +12 more
europepmc   +1 more source

Repurposing FDA-approved drugs and natural compounds to inhibit the RNA-dependent RNA polymerase domain of dengue virus 2 or dengue virus 3. [PDF]

Sci Rep
Ahmadi K, Jahantigh HR, Ahmadi N, Shahbazi B.   +3 more
europepmc   +1 more source

Reflection confocal microscopy for quantitative assessment of airway surface layer dysregulation and pharmacological rescue in cystic fibrosis under near-physiological conditions. [PDF]

Sci Rep
Agircan AS, Lampe M, Scheuermann H, Albrecht T, Graeber SY, Balázs A, Baumann I, Block S, Pepperkok R, Mall MA, Duerr J.   +10 more
europepmc   +1 more source

Inflammatory response in CF airway epithelial cells: a comparative study of modulators and wild-type CFTR rescue. [PDF]

Front Pharmacol
Kouadri A, Lyko C, El Hajjar C, Cormenier J, Kevin Gemy K, Alfaidy N, Benharouga M.   +6 more
europepmc   +1 more source

Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients-a systematic review. [PDF]

Front Pediatr
Pietrzykowska A, Darmoń J, Szymocha K, Donocik W, Tarasiewicz M, Stadnik J, Jarosz-Chobot P.   +6 more
europepmc   +1 more source

Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

Health Technol Assess
Edwards SJ, Farrar BG, Ennis K, Downes N, Wakefield V, Mackenzie I, Walters A, Jhita T.   +7 more
europepmc   +1 more source

Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Respir Res
Mouchtaridi E, Kowalik A, Raineri EJM, Humbert M, Jägerstedt J, Bojarlind M, Nilsson K, Flodström-Tullberg M, Pincikova T, Sandberg JK.   +9 more
europepmc   +1 more source

Arterialized oxygen tension and unfavorable clinical outcomes in pediatric cystic fibrosis. [PDF]

Front Pediatr
Gaupmann R, Gruber S, Schmidthaler K, Pauger B, Mersi B, Graf A, Szépfalusi Z, Renner S, Dehlink E.   +8 more
europepmc   +1 more source

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports. [PDF]

Respir Med Case Rep
van Mourik P, van der Hout EC, Luijk HD, Hofland RW, Bruns AHW, Heijerman HGM, Bronsveld I.   +6 more
europepmc   +1 more source